Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Ascent Resources ask shareholders for ability to raise funds


Regulatory News


Result of AGM

Thu, 8th Nov 2018 15:39


RNS Number : 8278G
Clinigen Group plc
08 November 2018

8 November 2018

Result of AGM

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, held its Annual General Meeting ("AGM") today at which all resolutions were passed.

The Board notes the voting results around two resolutions and will continue to have close dialogue with our shareholders to ensure that they and the Group are closely aligned.

At the meeting, Peter Allen, Clinigen's Chairman reiterated that the Group is well positioned to deliver another year of good progress, as set out at the recent full year results.

Full details of the poll results and the slides from the presentation given by the Group will be made available on Clinigen's website www.clinigengroup.com.

- Ends -

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Martin Abell, Group Chief Executive Officer

Matt Parrish, Head of Investor Relations




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)




RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Alex Shaw / Deborah Bell

Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGUWOVRWBAARAA


Related Shares:
Clinigen Group (CLIN)



Back to Regulatory News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.